HTG Molecular is preparing a triad of submissions for its Edge System in the US, EU, and Canada, a company executive said this week.
TUCSON, Ariz.—HTG Molecular Diagnostics and the Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) have finalized a license agreement that provides HTG exclusive rights to commercialize PROOF Centre-developed gene expression blood tests to evaluate the prognosis of chronic obstructive pulmonary disease (COPD) patients who are likely to experience frequent exacerbations known as lung attacks.
After a major nuclear accident, identifying early on which victims were zapped with the most radiation could help save lives.
TUCSON, Ariz.—HTG Molecular Diagnostics is collaborating with the John Wayne Cancer Institute (JWCI) to market its melanoma signature assays.
A biomarker discovery collaboration between HTG Molecular Diagnostics and Sanofi US will use HTG’s quantitative nucleic acid protection, or qNPA, technology to identify molecular targets in white blood cells associated with response to an unnamed cancer drug.
Cowboy boots and rodeos. White coats and laboratories. They’re both a great match for Tucson.
ADVANCE talks with TJ Johnson, CEO of HTG Molecular Diagnostics, about the future of the clinical laboratory.
For more than a decade, homegrown biotech firm High Throughput Genomics Inc. has been focused on providing genetic testing materials and related services for drug research.
Page last updated May 20, 2020